What Nystatine Treats: Main Uses and Benefits

---

Quick Facts

• Oral Cavity: Supports the management of fungal infections in the mouth, such as oral candidiasis (thrush).
• Skin: Utilized in the treatment of cutaneous or mucocutaneous mycotic infections, particularly those caused by Candida species.
• Gastrointestinal Tract: Employed for addressing fungal infections affecting the lining of the stomach and intestines.

---

Nystatine is a medication used in the management of fungal and yeast infections. Its therapeutic function is primarily directed toward infections caused by Candida albicans and other susceptible Candida species. It assists in resolving conditions affecting various areas of the body.

Infections of the oral cavity, commonly known as oral candidiasis or thrush, are a key indication for the use of Nystatine oral suspension. The medication may be applied to the mouth to help improve symptoms associated with this condition.

For cutaneous (skin) and mucocutaneous infections, Nystatine preparations like creams or ointments are utilized. This includes addressing diaper rash and other skin surface infections caused by susceptible fungi. Furthermore, the medication may be prescribed to address non-esophageal fungal infections of the gastrointestinal tract.

Regulatory References

1. NIH MedlinePlus guidance

Eligibility Map: Who Can and Cannot Use Nystatine — Official Regulatory Information

Populations for whom use is contraindicated:

• Patients with a history of hypersensitivity (allergy) to nystatin or any component of the specific preparation (e.g., excipients).

Eligibility Classifications	Classification	Population/Condition
Contraindicated	Hypersensitivity to Nystatin or Excipients
Not Recommended	Hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency (for sucrose-containing oral suspensions)

Age and Physiological State Rules

• Age-Related Rules: While most adults and children can use Nystatine, oral tablets or lozenges are typically not recommended for children younger than five years of age who may be too young to use them safely. The oral suspension is preferred for this age group.
• Pregnancy/Lactation Status: Due to negligible absorption, Nystatine is generally considered low risk. However, official labeling advises it should only be prescribed during pregnancy and lactation if the potential benefits are clearly considered to outweigh the possible risks. It is not known if Nystatin is excreted in human milk.

Eligibility-Related Restrictions

• The medication is not effective and therefore not for use in the treatment of systemic mycoses (widespread, internal fungal infections).
• Specific topical and oral formulations are restricted by the route of administration; for instance, topical powder/cream formulations are not for ophthalmic use (use in the eye).

Connection to the overall eligibility profile: Regulatory documents establish the primary non-eligibility rule as an absolute contraindication for known hypersensitivity to the drug or its inactive ingredients. Beyond this exclusion, eligibility is defined by constraints, prohibiting its use for systemic infections and restricting its application to the specific topical or oral sites for which the formulation is approved, ensuring it is only used as a non-absorbed treatment.

Interactions with other medicines and products

Nystatine’s official regulatory interaction profile is defined by its core characteristic: negligible systemic absorption following oral or topical administration. This means Nystatine does not typically participate in classical systemic drug–drug interactions involving metabolic pathways such as Cytochrome P450 (CYP) enzymes or drug transporters, as confirmed by regulatory agencies.

Interactions are primarily local, pharmacodynamic constraints, strictly limited to the drug’s site of application. These include:

• Formal Contraindications: Co-administration is restricted with allogeneic cultured keratinocytes/fibroblasts in bovine collagen (a type of tissue graft) due to the risk of local product degradation from the topical antifungal agent.

• Antagonism of Supplements: The local antifungal activity of Nystatine can potentially inactivate or decrease the therapeutic effect of products containing live yeast, such as certain probiotics (e.g., Saccharomyces boulardii) or Brewer’s yeast supplements.

• Other Antifungals: Co-administration with certain other antifungals may result in a documented reduction in the local activity of the co-administered agent.

• Population Notes: Regulatory notes advise monitoring when Nystatine is used with agents associated with nephrotoxicity or ototoxicity, such as Voclosporin, and note the potential for increased absorption of the co-administered corticosteroid in pediatric patients using fixed-combination topical products.

No mandatory timing separation rules are specified in the official labeling.

Targeted Fungal Cell Membrane Disruption

The core mechanism involves the active ingredient's specific and high-affinity binding to ergosterol, a crucial sterol component unique to the fungal plasma membrane. This interaction physically inserts Nystatin molecules into the membrane, causing them to aggregate and form hydrophilic, transmembrane pores. This direct, physical action initiates the process of fungal cell death and determines the drug’s localized scope of activity, as it demonstrates selectivity by preferring fungal ergosterol over human cholesterol.

---

Mechanism-Driven Collapse of Cellular Integrity

The pores created by Nystatin result in the unregulated loss of intracellular components, most critically the rapid efflux of monovalent cations like potassium ions (K^+). This leakage immediately abolishes the electrochemical gradient and the osmotic balance required for fungal cellular function, leading to irreversible metabolic failure and cell lysis. This establishes the targeted fungicidal physiological consequence at the application site, without depending on systemic processes.

How to Use Nystatin: Administration Guidelines

Nystatin is administered via local routes only, consistent with its negligible systemic absorption, and is not used for generalized or invasive mycoses. Administration is defined by the dosage form tailored for the infection site.

---

Dosing and Administration Routes

Administration Route	Typical Adult Dosing Range	Standard Frequency
Oral Suspension (for mouth infections)	400,000 to 600,000 units per dose	Four times daily (QID)
Oral Tablets (for intestinal infections)	500,000 to 1,000,000 units per dose	Three times daily (TID)
Topical Forms (Cream, Ointment, Powder)	Apply a thin layer to affected area	Two or three times daily

---

Key Procedural Instructions

For oral suspension used to treat candidiasis of the mouth, the medication bottle must be shaken well prior to use. Standard practice involves retaining the liquid in the mouth or swishing it for as long as possible before swallowing; this is intended to maximize local contact with the fungal lesions. The dose is often divided, with half administered to each side of the mouth.

For infants, the dose is typically 200,000 units (2 mL) four times daily. Avoiding feeding for five to ten minutes after administration helps to preserve the necessary contact time between the drug and the infection site.

Treatment duration is determined by clinical response. Use typically continues for at least 48 hours after symptoms have disappeared and evidence indicates eradication of the Candida infection. Topical preparations are strictly for external use and must not be used on the eye.

Research evidence / Overview of studies for Nystatin

---

Evidence for use in Oral and Mucocutaneous Fungal Infections

For treating infections of the mouth (thrush), short-term randomized controlled trials (RCTs) and systematic reviews have explored various Nystatin forms, such as oral suspension. Researchers examined changes in symptoms, measured as the resolution of visible symptoms, and the fungal clearance measures. These studies explored how symptoms evolved in observed populations, including newborns, infants, children, and adults with oral fungal infections, over typical treatment durations of one to four weeks.

For fungal infections of the skin or skin folds, such as candidal diaper dermatitis, evidence was derived from regulatory clinical trials and comparative observational studies. These studies monitored outcomes related to physical discomfort and inflammatory states, specifically focusing on the resolution of visible symptoms. Studies described observed patterns of clearance in specific low-risk populations, and patterns generally align with those observed for locally acting agents.

---

Evidence for Prophylaxis of Fungal Colonization in High-Risk Infants

Research has examined Nystatin as a prophylactic agent—meaning a treatment was studied for prevention—in studies conducted on very low birth weight (VLBW) infants and premature neonates. These studies monitored the occurrence rate of Invasive Fungal Infection (IFI) and the frequency of fungal colonization.

Studies indicate that use in this specific setting was associated with observed changes in colonization and IFI rates. However, some meta-analyses reported that outcomes, such as overall mortality rate or length of NICU stay, were not observed to be substantially different from those in control groups. The findings were mixed regarding its effect on these broader outcomes when compared to control groups or alternative prophylactic agents.

---

Evidence Consistency and Research Gaps

Research patterns were noted to be more consistent in studies of generally healthy individuals with localized infections. Certainty levels were described as low or moderate when research explored outcomes in complex or high-risk populations. Comparative research has explored its use with systemic antifungal drugs, and those findings related to clinical outcomes were often mixed.

Research limitations include follow-up durations that were limited across many trials, resulting in a lack of data on long-term outcomes. Furthermore, comparative evidence is lacking, specifically in contemporary, large-scale randomized controlled trials that fully compare Nystatin topical forms to newer alternative treatments. Subgroup findings remain uncertain in severely immunocompromised patient groups.

Key Studies & References

1. Nystatin Oral Suspension Label: Regulatory Monograph
2. Treatment for oral candidiasis in immunocompromised patients: systematic review and meta-analysis of randomized controlled trials

Common questions about Nystatine (FAQ)

Q: How long does it take for Nystatin to start working?

According to official product information, Nystatin acts directly at the infection site. Clinical studies and regulatory guidance indicate that symptomatic relief is often reported to begin within 24 to 72 hours after starting treatment.

---

Q: Can Nystatin affect birth control pills or other medicines I take orally?

Official labeling explains that Nystatin is absorbed insignificantly into the bloodstream after oral use, meaning plasma concentrations are usually undetectable. Because systemic absorption is minimal, the medication is not expected to participate in classic systemic drug-drug interactions that affect many orally taken medications.

---

Q: Can I drink water or eat right after using the oral suspension?

To support the drug's effectiveness, the product information recommends avoiding eating or drinking anything for a specific period, often 20 to 30 minutes, after using the oral suspension. This procedure is important to maximize the necessary contact time between the medication and the infection site in the mouth.

---

Q: Is it safe to use Nystatin while pregnant or breastfeeding?

Regulatory documents state Nystatin is generally advised during pregnancy only when the potential benefits are clearly considered to outweigh the possible risks. It is also not known whether Nystatin is excreted in human milk, and caution is advised when the drug is administered to a nursing patient.

---

Q: Does Nystatin interact with probiotic supplements like Saccharomyces boulardii?

As an antifungal agent, Nystatin can potentially be active against certain live yeasts, such as those used in some probiotic supplements. Some regulatory notes acknowledge this potential local antagonism, and certain medical guidelines suggest separating the administration of the antifungal and live-yeast products.

---

Q: If I forget a dose of Nystatin, what should I do?

Regulatory patient information generally advises that a missed dose may be taken or used as soon as it is remembered. However, if it is close to the time for the next scheduled dose, it may be appropriate to skip the forgotten dose and return to the normal schedule. It is advised not to take two doses at once to make up for a missed dose.

---

Q: What are the inactive ingredients in Nystatin oral suspension (e.g., is there sugar)?

The official product description details the inactive components in the oral suspension. These ingredients include a significant amount of sucrose (sugar), which is relevant for individuals with certain medical conditions, along with alcohol (typically le 1% v/v), glycerin, and parabens.

---

Q: What should I do if my child swallows too much Nystatin?

According to the product information on overdosage, oral doses higher than five million units daily have been known to cause effects such as nausea and general gastrointestinal upset. However, there have been no reports of serious systemic toxic effects linked to overdosage. Official guidance indicates that in the event of overdosage, contacting a poison control center or seeking medical attention is generally advised.

---

Q: Does alcohol consumption affect Nystatin treatment?

The Nystatin oral suspension contains a small amount of alcohol (up to le 1% v/v) as an inactive ingredient. Given the drug's negligible systemic absorption from the gut and skin, there are typically no specific regulatory warnings regarding the consumption of alcoholic beverages during the course of treatment.

---

Q: Can I mix the oral suspension with food or drinks to make it taste better?

Regulatory patient guidance advises against mixing the oral suspension with food or drinks. This can reduce the concentration and necessary contact time of the medication on the infection site, which is essential for maximizing its intended local effect.

---

Q: Where do I dispose of old Nystatin medication?

Unused or expired Nystatin should not be flushed down the toilet. If a drug take-back program is available in the area, this is the preferred disposal method. If no such program exists, official guidance recommends mixing the product with an unappealing substance, sealing it in a bag, and discarding it with household trash.

How to Store and Dispose of Nystatin

Nystatin's stability requires adherence to specific regulatory storage conditions. Most forms must be stored at Controlled Room Temperature, typically 20 C to 25 C. The medication must be protected from light and moisture and kept in a tightly closed container.

Handling and Protection

The oral suspension formulation must be protected from freezing. A mandatory requirement for all forms is to keep the product out of the reach and sight of children.

Disposal Instructions

Regulatory instructions require that unused or expired Nystatin not be flushed down the toilet. If a drug take-back program is unavailable, the product should be mixed with an unappealing material like dirt or used coffee grounds, sealed in a bag, and then discarded in the household trash.